CTMX vs SNPS · rev $138.1M vs P/E 63, rev $7.16B
CytomX Therapeutics Inc (CTMX) versus Synopsys Inc (SNPS) — a side-by-side from cached financials, not a winner call.
CytomX Therapeutics Inc (CTMX) is a biotechnology company listed on US.
Synopsys Inc (SNPS) is a software - infrastructure company listed on US.
Latest reported CTMX revenue for 2024-12-31 was $138.1M. Net income was $31.9M. Revenue was up 36.4% from 2023-12-31 to 2024-12-31. CTMX currently screens at market cap $653.1M.
Latest reported SNPS revenue for 2026-07-31 was $7.16B. Net income was $627.9M. Revenue was up 52.9% from 2026-04-30 to 2026-07-31. SNPS currently screens at market cap $85.14B and trailing P/E 63.3.
CTMX currently screens at market cap $653.1M. SNPS currently screens at market cap $85.14B and trailing P/E 63.3.
Not investment advice. Open the CTMX and SNPS stock pages for the full models.
Not investment advice.